Loading stock data…
EOLS
$5.58+0.25 (+4.69%)
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evolus, Inc. in the Healthcare sector is trading at $5.58. The stock is currently 54% below its 52-week high of $12.15, remaining 9.0% below its 200-day moving average. Technical signals show overbought RSI of 77 and bullish MACD crossover, explaining why EOLS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 77) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.58
Potential Upside
5%
Whystock Fair Value$5.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$14.67+162.8%
Range$10.00 – $20.00
Fundamentals
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the te...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$337.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
268.31%
Volume
Today's trading volume
1.97M
Recent News
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Evolus Q1 Earnings Call Highlights
Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year 2026 outlook for double-digit revenue growth and adjusted EBITDA profitability. First-quarter results
Evolus (EOLS) Q2 2025 Earnings Call Transcript
David Moatazedi: Thank you, Nareg, and good afternoon, everyone. Internationally, the business continues to deliver strong performance and is increasingly contributing to our growth trajectory as we expand our global footprint in key markets.
How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions
Evolus is back in focus after analysts revisited their price target framework, keeping the fair value unchanged at $14.67 per share. Some see the maintained target as confirmation that the core thesis is intact, while others read the previous $4 cut as a sign that expectations around long term revenue may have been reset. As you read on, you will see how to interpret this evolving analyst narrative and what to watch if you are tracking Evolus from here. Analyst Price Targets don't always...
April 2026's Leading Growth Stocks With Insider Confidence
The United States market has shown robust performance, rising 3.4% over the last week and an impressive 35% over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.